Testing terfenadine for relapsing multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether terfenadine, an allergy medicine, is safe and helpful for people with relapsing-remitting multiple sclerosis (MS). It may reduce MS activity and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed diagnosis of relapsing-remitting multiple sclerosis.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and use effective birth control during the study.
- You must be able to understand the study and give your consent (or have a legal representative do so).
- You cannot be taking certain medications that interact with terfenadine, such as certain antifungal drugs or certain antibiotics.
- You must not have certain heart problems, liver problems, or active infections, and you must be able to have MRI scans and a lumbar puncture.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests whether adding taurine – a natural amino acid – to your usual MS medication can help manage symptoms and slow the disease. If you are already on a stable MS treatment, this extra supplement might offer additional benefits.
This study looks at how the oral medication teriflunomide (Aubagio) affects tiredness and daily activities in people with relapsing forms of multiple sclerosis. If you are starting this treatment as part of your regular care, the study will track your experience over a year to see how it impacts your energy and function.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Hear when a new Relapsing Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.